Tislelizumab monotherapy in patients with previously untreated early-stage classical Hodgkin lymphoma: a real-world study
AbstractThe anti-PD-1 antibodies have been reported to show a striking effect in relapsed and refractory(R/R) classical Hodgkin lymphoma (cHL), however, there is still limited real-world data assessing the role of anti-PD-1 antibody monotherapy in early-stage cHL. In this retrospective analysis, we reported the effectiveness and safety of tislelizumab monotherapy in the first-line therapy of early-stage cHL. Twenty-three consecutive patients (10 males and 13 females) with previously untreated stage I A-II B cHL were included. At interim evaluation after 2 doses of tislelizumab monotherapy, 11 of 23 patients (47.8%) achieve...
Source: Annals of Hematology - February 14, 2024 Category: Hematology Source Type: research
A different perspective on PET/CT before treatment in patients with Hodgkin lymphoma: importance of volumetric and dissemination parameters
AbstractThe aim of this study is to investigate the role of the combination of volumetric and dissemination parameters obtained from pretreatment 18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in predicting the interim response and progression status in patients with Hodgkin lymphoma (HL). Pretreatment PET/CT images of HL patients were analyzed with LIFEx software, and volumes of interest (VOIs) were drawn with a fixed SUV 4.0 threshold. MTV, SUVmax, and TLG values were obtained from each VOI. Total MTV (tMTV) was calculated by summing the MTV values in all VOIs, and similarly, tota...
Source: Annals of Hematology - February 14, 2024 Category: Hematology Source Type: research
Clinical Profile and Outcome of Adult Classical Hodgkin ’s Lymphoma: Real World Single Centre Experience
AbstractHodgkin ’s lymphoma treatment outcomes have been the true success story of modern medicine. Various data from western as well as Indian studies are available for classical Hodgkin’s lymphoma (cHL). Here we report treatment outcomes from a tertiary cancer care centre in Karnataka over a 5 year period. T his was a retrospective review of cHL cases aged 15 years and above diagnosed between January 2015 and December 2019 at Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India. The case files of the patients were retrieved and relevant data was collected. Two hundred patients of cHL were included in ...
Source: Indian Journal of Hematology and Blood Transfusion - February 9, 2024 Category: Hematology Source Type: research
Epidemiologic and Clinical Patterns of Malignant Lymphoma in Qatar 2013-2017: A population-based Cohort Study
CONCLUSIONS: Diffuse large B-cell lymphoma emerged as the most prevalent subtype among lymphomas in Qatar. Generally, HL exhibited superior survival rates, at 67% compared to 60% for NHL. Minor deflation in survival rates, particularly for HL, might be attributed to Qatar's immigration patterns.PMID:38320544 | DOI:10.1159/000536567 (Source: Oncology)
Source: Oncology - February 6, 2024 Category: Cancer & Oncology Authors: Ahmad A Adel Aimilia Exarchakou Nurhan Elshafey Hafedh Ghazouani Awni Alshurafa Mohamed A Yassin Source Type: research
Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL
ConclusionThe patient achieved complete remission and long-term disease-free survival of months and continues to be followed up. The combination therapy model in this case may provide guidance for the management of relapsed/refractory ALK+ ALCL, and further prospective trials are needed to confirm its effectiveness. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - February 5, 2024 Category: Allergy & Immunology Source Type: research
14-3-3 η Proteins as a Diagnostic Marker, Disease Activation Indicator, and Lymphoma Predictor in Patients with Primary Sjögren Syndrome
CONCLUSION: 14-3-3η proteins are potential candidates for diagnostic marker, marker of disease activity, and predictor of lymphoma in PSS patients.PMID:38310415 | PMC:PMC10862092 | DOI:10.34172/aim.2023.85 (Source: Archives of Iranian Medicine)
Source: Archives of Iranian Medicine - February 4, 2024 Category: Middle East Health Authors: Ahmet Kor Merve Yal çın Şükran Erten Y üksel Maraş Esra F ırat Oğuz İsmail Doğan Ebru Atalar Salih Ba şer Özcan Erel Source Type: research
14-3-3 η Proteins as a Diagnostic Marker, Disease Activation Indicator, and Lymphoma Predictor in Patients with Primary Sjögren Syndrome
CONCLUSION: 14-3-3η proteins are potential candidates for diagnostic marker, marker of disease activity, and predictor of lymphoma in PSS patients.PMID:38310415 | PMC:PMC10862092 | DOI:10.34172/aim.2023.85 (Source: Archives of Iranian Medicine)
Source: Archives of Iranian Medicine - February 4, 2024 Category: Middle East Health Authors: Ahmet Kor Merve Yal çın Şükran Erten Y üksel Maraş Esra F ırat Oğuz İsmail Doğan Ebru Atalar Salih Ba şer Özcan Erel Source Type: research
14-3-3 η Proteins as a Diagnostic Marker, Disease Activation Indicator, and Lymphoma Predictor in Patients with Primary Sjögren Syndrome
CONCLUSION: 14-3-3η proteins are potential candidates for diagnostic marker, marker of disease activity, and predictor of lymphoma in PSS patients.PMID:38310415 | PMC:PMC10862092 | DOI:10.34172/aim.2023.85 (Source: Archives of Iranian Medicine)
Source: Archives of Iranian Medicine - February 4, 2024 Category: Middle East Health Authors: Ahmet Kor Merve Yal çın Şükran Erten Y üksel Maraş Esra F ırat Oğuz İsmail Doğan Ebru Atalar Salih Ba şer Özcan Erel Source Type: research
14-3-3 η Proteins as a Diagnostic Marker, Disease Activation Indicator, and Lymphoma Predictor in Patients with Primary Sjögren Syndrome
CONCLUSION: 14-3-3η proteins are potential candidates for diagnostic marker, marker of disease activity, and predictor of lymphoma in PSS patients.PMID:38310415 | PMC:PMC10862092 | DOI:10.34172/aim.2023.85 (Source: Archives of Iranian Medicine)
Source: Archives of Iranian Medicine - February 4, 2024 Category: Middle East Health Authors: Ahmet Kor Merve Yal çın Şükran Erten Y üksel Maraş Esra F ırat Oğuz İsmail Doğan Ebru Atalar Salih Ba şer Özcan Erel Source Type: research
14-3-3 η Proteins as a Diagnostic Marker, Disease Activation Indicator, and Lymphoma Predictor in Patients with Primary Sjögren Syndrome
CONCLUSION: 14-3-3η proteins are potential candidates for diagnostic marker, marker of disease activity, and predictor of lymphoma in PSS patients.PMID:38310415 | PMC:PMC10862092 | DOI:10.34172/aim.2023.85 (Source: Archives of Iranian Medicine)
Source: Archives of Iranian Medicine - February 4, 2024 Category: Middle East Health Authors: Ahmet Kor Merve Yal çın Şükran Erten Y üksel Maraş Esra F ırat Oğuz İsmail Doğan Ebru Atalar Salih Ba şer Özcan Erel Source Type: research
14-3-3 η Proteins as a Diagnostic Marker, Disease Activation Indicator, and Lymphoma Predictor in Patients with Primary Sjögren Syndrome
CONCLUSION: 14-3-3η proteins are potential candidates for diagnostic marker, marker of disease activity, and predictor of lymphoma in PSS patients.PMID:38310415 | PMC:PMC10862092 | DOI:10.34172/aim.2023.85 (Source: Archives of Iranian Medicine)
Source: Archives of Iranian Medicine - February 4, 2024 Category: Middle East Health Authors: Ahmet Kor Merve Yal çın Şükran Erten Y üksel Maraş Esra F ırat Oğuz İsmail Doğan Ebru Atalar Salih Ba şer Özcan Erel Source Type: research
14-3-3 η Proteins as a Diagnostic Marker, Disease Activation Indicator, and Lymphoma Predictor in Patients with Primary Sjögren Syndrome
CONCLUSION: 14-3-3η proteins are potential candidates for diagnostic marker, marker of disease activity, and predictor of lymphoma in PSS patients.PMID:38310415 | PMC:PMC10862092 | DOI:10.34172/aim.2023.85 (Source: Archives of Iranian Medicine)
Source: Archives of Iranian Medicine - February 4, 2024 Category: Middle East Health Authors: Ahmet Kor Merve Yal çın Şükran Erten Y üksel Maraş Esra F ırat Oğuz İsmail Doğan Ebru Atalar Salih Ba şer Özcan Erel Source Type: research
14-3-3 η Proteins as a Diagnostic Marker, Disease Activation Indicator, and Lymphoma Predictor in Patients with Primary Sjögren Syndrome
CONCLUSION: 14-3-3η proteins are potential candidates for diagnostic marker, marker of disease activity, and predictor of lymphoma in PSS patients.PMID:38310415 | PMC:PMC10862092 | DOI:10.34172/aim.2023.85 (Source: Archives of Iranian Medicine)
Source: Archives of Iranian Medicine - February 4, 2024 Category: Middle East Health Authors: Ahmet Kor Merve Yal çın Şükran Erten Y üksel Maraş Esra F ırat Oğuz İsmail Doğan Ebru Atalar Salih Ba şer Özcan Erel Source Type: research
14-3-3 η Proteins as a Diagnostic Marker, Disease Activation Indicator, and Lymphoma Predictor in Patients with Primary Sjögren Syndrome
CONCLUSION: 14-3-3η proteins are potential candidates for diagnostic marker, marker of disease activity, and predictor of lymphoma in PSS patients.PMID:38310415 | PMC:PMC10862092 | DOI:10.34172/aim.2023.85 (Source: Archives of Iranian Medicine)
Source: Archives of Iranian Medicine - February 4, 2024 Category: Middle East Health Authors: Ahmet Kor Merve Yal çın Şükran Erten Y üksel Maraş Esra F ırat Oğuz İsmail Doğan Ebru Atalar Salih Ba şer Özcan Erel Source Type: research
14-3-3 η Proteins as a Diagnostic Marker, Disease Activation Indicator, and Lymphoma Predictor in Patients with Primary Sjögren Syndrome
CONCLUSION: 14-3-3η proteins are potential candidates for diagnostic marker, marker of disease activity, and predictor of lymphoma in PSS patients.PMID:38310415 | PMC:PMC10862092 | DOI:10.34172/aim.2023.85 (Source: Archives of Iranian Medicine)
Source: Archives of Iranian Medicine - February 4, 2024 Category: Middle East Health Authors: Ahmet Kor Merve Yal çın Şükran Erten Y üksel Maraş Esra F ırat Oğuz İsmail Doğan Ebru Atalar Salih Ba şer Özcan Erel Source Type: research
